山東墨龍(00568.HK):2022年淨利潤-4.25億元
格隆匯3月31日丨山東墨龍(00568.HK)發佈公吿,截至2022年12月31日止年度,報吿期內,集團實現營業收入人民幣27.66億元,同比下降25.94%;實現歸屬於上市公司股東的淨利潤人民幣-4.25億元。報吿期內,因部分產品訂單不足,導致產品銷量下降及營業收入減少;原材料採購及產品銷售運輸受限,部分生產線開工不足,以及主要原材料(煤炭)價格上升等,綜合導致生產成本及管理費用增加,產品毛利率下降;根據相關規定,集團對超額虧損子公司壽光寶隆石油器材有限公司的債權計提信用減值損失,影響合併財務報表中“歸屬於母公司所有者的淨利潤”人民幣6797.12萬元。上述因素綜合導致集團經營業績出現虧損。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.